5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The market is segmented by organ type, application, end user (pharmaceutical and biotechnology companies, and academic and research institutes), and geography
Fastest Growing Market:
An organ-on-a-chip is a microfluidic cell culture device that contains continuously perfused chambers. This chip develops a narrow channel for the blood and air flow in organs, such as lung, gut, liver, heart, and other organs. Such devices produce multiple levels of tissue and organ functionalities, which are not feasible using conventional 2D and 3D culture systems. It offers a wide range of applications, such as diseases modeling, patient stratification, and phenotypic screening.
The organ-on-chip market is driven by factors, such as a requirement for alternatives for animal testing, need for early detection of drug toxicity, and new product launches and advancements in technology that are also responsible for driving the market. Furthermore, the surging initiatives by pharmaceutical companies, to invest and investigate drug repurposing utilizing organs-on-chips models, are also expected to drive the growth of the organs-on-chip market.
The demand for personalized medication and the vast applications of organ-on-chip beyond the pharmaceutical industry are the major factors creating growth opportunities for market players.
There are also increasing product launches by several key players, intended to expand their product portfolio, which are further expected to increase their market in the upcoming forecast years.
The market studied is greatly influenced by the launches of new products by the major market players, which is further expected to increase their market shares in the coming years. For instance, in March 2017, InSphero AG launched the 3D InSight Monkey Liver Microtissues, which resulted in the expansion of the company’s suite of organotypic 3D liver models for in vitro safety and efficacy testing.
An organ-on-chip (OOC) is also called as multi-channel 3D microfluidic cell culture chip. It is a type of artificial organ that simulates activities, mechanics, and physiological responses of entire organs and organ systems. The size of the OOC is about an AA battery, and its transparency allows to see the organ’s functionality, behavior, and response at the cellular and molecular levels.
|By Organ Type|
|Other Organ Types|
|By End User|
|Pharmaceutical and Biotechnology Companies|
|Academic and Research Institutes|
|Other End Users|
|Rest of the World (ROW)|
Report scope can be customized per your requirements. Click here.
The drug discovery segment of the organ-on-chip market is expected to hold the largest market share, and is projected to witness a CAGR of 34.72% during the forecast period.
The pharmaceutical industry is facing many challenges due to the rising cost and declining efficiency of drug R&D. Thus, there is a critical need for new testing approaches for generating reliable predictions of drug efficacy. OOC has the potential to serve as a new enabling platform for the identification and validation of efficacy, safety, and durability of potential targets early in the pipeline, thus ncreasing the chances of success in clinical trials.
Eventually, OOC models may play a pivotal role in streamlining the clinical trial processes. For instance, advances in stem cell engineering could be integrated into the OOC technology to develop personalized models to predict patient-specific toxicity and efficacy, which could lead to more efficient human trials with significantly reduced preclinical testing requirements. The OOC technology can be mutually integrated with modeling and analysis tools in the drug discovery process. Furthermore, the OOC models could be used to validate potential targets identified by genomics and proteomics analyses. These developments have the potential to transform the process of drug discovery and development in the future, which may contribute directly to the growth of the market.
To understand key trends, Download Sample Report
North America currently dominates the OOC market owing to factors, such as the availability of a wide range of services offered by major players (which includes customized designing of new chips with specific organ arrangement) and increase in toxicological testing of chemicals on the different types of organ cells. Huge investments are being made by the public and private institutes for their research. For instance, the Wyss Institute received almost USD 5.6 million in grant money from the US FDA to use its organ-on-chip technology to test human physiological responses to radiation and to evaluate drugs designed to counter those effects.
To understand geography trends, Download Sample Report.
The organ-on-chip market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The presence of major market players, such as AxoSim Inc., BiomimX SRL, Elveflow, Emulate Inc., Hurel Corporation, InSphero AG, MIMETAS BV, Nortis Inc., Tara Biosystems, and TissUse GmbH, is, in turn, increasing the overall competitive rivalry in the market. Product advancements and improvements in the organ-on-chip platforms by the major players are increasing the competitive rivalry.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Requirement of Alternative for Animal Testing
4.2.2 Need for Early Detection of Drug Toxicity
4.2.3 New Products Launches and Advancements in Technology
4.3 Market Restraints
4.3.1 Complexity of Organ-on-chip Models
4.4 Industry Attractiveness Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Organ Type
5.1.4 Other Organ Types
5.2 By Application
5.2.1 Drug Discovery
5.2.2 Toxicology Research
5.2.3 Other Applications
5.3 By End User
5.3.1 Pharmaceutical and Biotechnology Companies
5.3.2 Academic and Research Institutes
5.3.3 Other End Users
5.4.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.4.4 Rest of the World (ROW)
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AxoSim Inc.
6.1.2 BiomimX SRL
6.1.4 Emulate Inc.
6.1.5 Hurel Corporation
6.1.6 InSphero AG
6.1.7 MIMETAS BV
6.1.8 Nortis Inc.
6.1.9 Tara Biosystems
6.1.10 TissUse GmbH
7. MARKET OPPORTUNITIES AND FUTURE TRENDS